Europe — EMA
Ongentys (Opicapone)
Opicapone, the active ingredient in Ongentys, is a catechol‑O‑methyltransferase (COMT) inhibitor presented as a tablet for oral use. It is indicated as an adjunct therapy for patients with Parkinson's disease…
Request sourcing
What is Opicapone?
Opicapone, the active ingredient in Ongentys, is a catechol‑O‑methyltransferase (COMT) inhibitor presented as a tablet for oral use. It is indicated as an adjunct therapy for patients with Parkinson's disease experiencing motor fluctuations. GNH USA supplies Ongentys as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Ongentys as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Opicapone used for?
Ongentys is a COMT‑inhibitor used in the management of Parkinson's disease and related motor complications. - Parkinson's disease with motor fluctuations: improves "on" time without increasing dyskinesia. - Adjunct to levodopa therapy: enhances and prolongs levodopa plasma concentrations. - Early‑stage Parkinson's disease: may be considered to delay the need for dose escalation of levodopa.
What are the side effects of Opicapone?
Adverse reactions reported with Opicapone are generally mild to moderate and reflect its pharmacologic activity.
Common Side Effects: - Nausea - Diarrhea - Dyskinesia - Dry mouth - Dizziness - Headache
Serious or Rare Side Effects: - Severe hepatic impairment - Anaphylactic reactions - Neuroleptic malignant‑like syndrome - Severe orthostatic hypotension - Persistent hallucinations - Elevated creatinine levels.
What precautions apply to Opicapone?
When using Opicap8
- ".
- " " " " " " "" " "" "" "" " "" "" "" ". -
